ONPH

Oncology Pharma (PK) Stock Price

0.457
0.00 (0.0%)
0.457
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Oncology Pharma Inc (PK) ONPH OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.457 16:25:17
Open Price Low Price High Price Close Price Prev Close
0.457 0.457
Bid Price Ask Price Spread News
0.376 1.50 1.12 - -
Trades Volume Avg Volume 52 Week Range
2 20 - 0.00395 - 0.85
Last Trade Time Type Quantity Stock Price Currency
11:21:02 10 $ 0.356 USD

Oncology Pharma (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 11.49M 25.13M 3.39M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
1.20k $ - 0.00% - -

more financials information »

Oncology Pharma (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ONPH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.420.850.420.48576281,5450.0378.81%
1 Month0.55670.850.420.46852661,195-0.0997-17.91%
3 Months0.410.850.250.48886881,3540.04711.46%
6 Months0.00930.850.003950.010737591,2530.44774,813.98%
1 Year0.0190.850.003950.0208982306,1570.4382,305.26%
3 Years0.010.850.0030.0263887268,6450.4474,470.0%
5 Years0.010.850.0030.0263887268,6450.4474,470.0%

Oncology Pharma (PK) Description

Oncology Pharma, Inc. is a pioneering oncology company dedicated to licensing, developing, manufacturing and commercializing therapeutics. The Company has assembled a team of executives and advisors with a proven multi-disciplinary expertise in the field of cancer therapies and leadership to identify, negotiate and amalgamate "best in class" research, technologies, and drug delivery that are synergistic and collaborative. Oncology Pharma has executed Letters of Intent with Kalos Therapeutics, with its lead anti-cancer bio-pharmaceutical (a peptide) medication, KTH-222. NanoSmart Pharmaceuticals' drug delivery platform can target many types of cancer and other diseases. Connect2Med, a powerful application used for recruiting, enrolling and supporting patients for clinical trials. Finally, the Company has entered into a Letter of Intent to acquire a 50% stake in Diagnomics, Inc., which is a "cutting edge" molecular diagnostic company in precision medicine, a CLIA and CAP accredited Laboratory that among other uses provides services to global pharmaceutical companies, including academic and biotech companies in San Diego, CA. Diagnomics' use of pharmacogenetics combined with artificial intelligence is a "game changer" in precision medicine, drug development, clinical trials, lowering of cost and time of clinical trials, a faster regulatory approval process and faster availability of drugs to the patients. Further information may be found at www.oncology-pharma.com.


Your Recent History
USOTC
ONPH
Oncology P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.